

NCPE Assessment

Plain English Summary

July, 2024

Drug name: Carfilzomib (pronounced (car-filz-oh-mib) in combination with daratumumab and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.

Brand name: Kyprolis®

HTA ID: 20054

What is the NCPE?

The National Centre for Pharmacoeconomics (NCPE) is a team of experts who look at the health benefits and costs of medicines. The HSE asks us to advise on whether or not a new medicine is good value for money. We give unbiased advice to help the HSE provide the most effective, safe and cost-effective (value for money) treatments for patients.

How do we make our recommendations?

Our main focus is on the health benefits and cost effectiveness of a medicine. We look at the wider costs and health benefits associated with a new medicine, for example:

- Does the new medicine work better than other treatments available in Ireland?
- Is the new medicine easier to give or easier to take compared with other treatments available in Ireland?
- Does the new medicine reduce the need for patients to be hospitalised?
- Does the new medicine improve the quality of a patient's life over other treatments available in Ireland?
- Will the new medicine save resources elsewhere within the health system?

We review the information from clinical trials along with the cost and value for money data presented by the pharmaceutical company. We ask doctors and other healthcare professionals for advice about any health benefits of the new medicine compared with current treatments. We also ask patient organisations to send us their views on how the new drug may improve patients' day-to-day experience of living with a disease.

What is carfilzomib used for?

Carfilzomib is a cancer medicine used to treat adults with multiple myeloma (cancer of the bone marrow). It is given to adults who have received at least one previous treatment for their cancer. In this assessment, carfilzomib is used in combination with the medicines daratumumab and dexamethasone.

What recommendation has the NCPE made to the HSE?

We have recommended that the HSE should not consider funding carfilzomib in combination with daratumumab and dexamethasone. The HSE will consider our recommendation and make the final decision about reimbursement (funding). When making the funding decision, the HSE will also consider the additional [criteria](#) outlined in the Health (Pricing and Supply of Medical Goods) Act 2013.

We have received a Patient Organisation Submission from Multiple Myeloma Ireland about carfilzomib in combination with daratumumab and dexamethasone and shared it with the HSE. This submission will form part of the data that the HSE considers.

Why did we make this recommendation?

After reviewing the data presented by the pharmaceutical company, we concluded that we did not receive enough information to clearly assess how well the medicine works compared with other ways of managing this condition. The price of the medicine is too high compared with other ways to manage this condition, and we believe that the medicine is very poor value for money.

The HSE considers a number of factors along with our recommendation when deciding whether to provide this medicine. These factors are listed in the Health (Pricing and Supply of Medical Goods) Act 2013.

Next steps

When the HSE receives our recommendation, it will look at all the relevant data about carfilzomib. The HSE makes the final decision on reimbursement.

Where can I get more information?

You can get more information about carfilzomib from the following online options:

- the NCPE Technical Summary Document
- Kyprolis European Public Assessment Report (EPAR) – [Summary for the public](#), or
- searching for carfilzomib on our website (www.ncpe.ie);
- searching for carfilzomib on the European Medicines Agency (EMA) website

(www.ema.europa.eu).

Please refer to the NCPE website for updated information on the reimbursement status of this medicine